CapsoVision (NASDAQ:CV) Upgraded by Roth Capital to Strong-Buy Rating

CapsoVision (NASDAQ:CV) was upgraded by research analysts at Roth Capital to a “strong-buy” rating in a note issued to investors on Monday, July 28th, MarketBeat reports. The brokerage presently has a $6.00 price objective on the stock. Roth Capital’s target price points to a potential upside of 46.34% from the stock’s current price. Roth Capital also issued estimates for CapsoVision’s Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.49) EPS, Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at ($0.04) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at ($0.01) EPS, FY2028 earnings at $0.35 EPS and FY2029 earnings at $0.58 EPS.

Other equities research analysts have also recently issued research reports about the company. Benchmark initiated coverage on CapsoVision in a research note on Monday, July 28th. They issued a “speculative buy” rating and a $5.00 price objective for the company. Wall Street Zen raised CapsoVision to a “hold” rating in a research report on Sunday, July 13th.

CapsoVision Trading Up 4.9%

CapsoVision stock traded up $0.19 during trading hours on Monday, hitting $4.10. The stock had a trading volume of 74,900 shares, compared to its average volume of 127,238. CapsoVision has a one year low of $3.49 and a one year high of $5.72.

CapsoVision Company Profile

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn’s disease.